Key result
Long-term use of proton pump inhibitors may be associated with increased cardiovascular risks in the general population, though current observational evidence is insufficient to alter clinical practice.
Why the study?
Do proton pump inhibitors increase cardiovascular risks in the general population with no history of cardiovascular diseases?
Do proton pump inhibitors increase cardiovascular risks in the general population with no history of cardiovascular diseases?
This review highlights that the cardiovascular risks associated with proton pump inhibitors may extend beyond patients with coronary artery disease to the general population.
Proton pump inhibitors (PPIs) are the most effective gastric acid-suppressing agents and the mainstay medical therapy for a series of acid peptic diseases. In general, the safety profile of PPIs is excellent. However, with long-term drug administration, the safety and potency of PPIs has been questioned. In the cardiovascular field, drug-drug interactions related to PPIs have been identified with particular attention regarding the use of PPIs combined with clopidogrel in patients with acute coronary syndrome. Currently, cardiovascular risks from PPIs may extend from patients with coronary artery disease to the general population. This review summarizes the possible cardiovascular risks in PPI users with no history of cardiovascular diseases and discusses possible biological mechanisms.
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2017) conducted a review in Cardiovascular risks. Proton pump inhibitors vs. Non-users or H2 blocker users was evaluated. Long-term use of proton pump inhibitors may be associated with increased cardiovascular risks in the general population, though current observational evidence is insufficient to alter clinical practice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: